CRB
With autologous cell therapies facing unsustainable COGS, US-based engineering firms (like CRB and IPS) are pioneering TEA models that simulate the financial impact of decentralized, "hospital-adjacent" manufacturing networks.
- Country
- United States
Commercial
Facility Design
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| consulting-strategy | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaema
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Techno-economic analysis (TEA) for bioprocesses | consulting-strategy | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.